Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 7Completed 6Unknown 2Recruiting 2Not yet recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 10Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Stomach Neoplasms 2Recurrence 2Head and Neck Neoplasms 2HER2-positive Breast Cancer 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Gastroesophageal Junction Cancer 1Esophageal Neoplasms 1Carcinoma, Squamous Cell 1Advanced or Metastatic Squamous Non-Small Cell Lung Cancer 1Advanced Solid Tumors 1Advanced Pancreatic Cancer 1Advanced Non-small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1Advanced Malignant Neoplasm 1Advanced Esophageal Carcinoma 1Advanced Breast Cancer 1

Interventions

Cyclophosphamide 6fludarabine 5toripalimab 3Paclitaxel 3Etoposide 3Carboplatin 3Bevacizumab 3zimberelimab 2tislelizumab 2sintilimab 2glumetinib 2Vincristine 2Temozolomide 2Platinum 2Immune Checkpoint Inhibitors 2Hepatectomy 2Gemcitabine 2Drug Therapy 2Docetaxel 2Cisplatin 2Capecitabine 2venetoclax 1relmacabtagene autoleucel 1osimertinib 1lenvatinib 1irinotecan sucrosofate 1glofitamab 1gallium maltolate 1fludarabine phosphate 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Recurrence × Docetaxel × Clear all
NCT06892431 2025-03-25

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Shanghai JMT-Bio Inc.

Phase 2 Not yet recruiting
150 enrolled
Head & Neck

Nasopharyngeal Neoplasms, Recurrence

NCT06525350 2024-07-29

A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Not yet recruiting
256 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡